U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07300514) titled 'Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma' on Dec. 10.
Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled phase III trial evaluating golidocitinib as maintenance therapy in adult patients with peripheral T-cell lymphoma (PTCL) who achieved complete response (CR) or partial response (PR) after first-line systemic chemotherapy and are not candidates for hematopoietic stem cell transplantation (HSCT) or decline HSCT. Eligible patients with histologically confirmed PTCL subtypes (PTCL-NOS, ALK-positive anaplastic large cell lymphoma [ALK-ALCL], angioimmunoblastic T...